Drugs codes by Medicare payment, 2024
Every code billed to Original Medicare Part B, with how many providers bill it and what it paid.
Top 200 drugs codes
The 200 with the most payment of 320 codes.
Not listed: 196 codes billed by fewer than 11 providers (small cells; each has its own page with the count).
| observed | calculated | calculated | calculated | calculated | calculated | ||
|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,155 | $1,756,326,820 | 11% | 2,690,616 | 559 | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 2,436 | $1,448,279,182 | 8.7% | 53,010,858 | 13,170 | |
| J9271 | Injection, pembrolizumab, 1 mg | 1,922 | $1,242,513,566 | 7.5% | 28,218,856 | 12,400 | |
| J0897 | Injection, denosumab, 1 mg | 9,797 | $978,864,123 | 5.9% | 48,156,716 | 2,760 | |
| Q4205 | Membrane graft or membrane wrap, per square centimeter | 288 | $676,084,642 | 4.1% | 652,199 | 990 | |
| 91320 | Descriptor not shown (CPT code) | 36,800 | $663,520,364 | 4.0% | 4,506,697 | 59 | |
| 91322 | Descriptor not shown (CPT code) | 31,346 | $564,768,020 | 3.4% | 3,668,923 | 54 | |
| 90662 | Descriptor not shown (CPT code) | 70,747 | $524,368,452 | 3.2% | 6,486,542 | 46 | |
| Q4271 | Complete ft, per square centimeter | 128 | $492,819,395 | 3.0% | 373,674 | 1,758 | |
| J0177 | Injection, aflibercept hd, 1 mg | 1,392 | $478,021,052 | 2.9% | 1,820,837 | 776 | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 1,247 | $440,285,869 | 2.6% | 13,105,162 | 8,300 | |
| 90677 | Descriptor not shown (CPT code) | 44,623 | $374,165,365 | 2.2% | 1,299,916 | 19 | |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 765 | $323,003,588 | 1.9% | 8,288,764 | 9,000 | |
| Q4191 | Restorigin, per square centimeter | 135 | $309,842,511 | 1.9% | 262,597 | 1,314 | |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 857 | $286,096,570 | 1.7% | 2,452,956 | 1,845 | |
| 90653 | Descriptor not shown (CPT code) | 43,932 | $282,893,756 | 1.7% | 3,476,036 | 41 | |
| Q4164 | Helicoll, per square centimeter | 60 | $253,202,004 | 1.5% | 207,296 | 945 | |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 1,339 | $241,453,680 | 1.5% | 28,416,634 | 14,490 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 3,723 | $225,551,859 | 1.4% | 46,383,230 | 7,660 | |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 958 | $220,117,291 | 1.3% | 61,165,045 | 45,600 | |
| J9299 | Injection, nivolumab, 1 mg | 441 | $191,282,270 | 1.1% | 7,881,796 | 14,180 | |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 1,076 | $178,627,979 | 1.1% | 19,861,793 | 13,650 | |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 470 | $169,309,392 | 1.0% | 937,303 | 1,124 | |
| J3262 | Injection, tocilizumab, 1 mg | 722 | $166,745,517 | 1.0% | 35,790,556 | 39,770 | |
| Q4262 | Dual layer impax membrane, per square centimeter | 38 | $144,140,040 | 0.87% | 159,311 | 821 | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 746 | $143,429,242 | 0.86% | 8,328,838 | 8,100 | |
| Q4276 | Orion, per square centimeter | 23 | $141,046,740 | 0.85% | 132,581 | 1,951 | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,377 | $137,038,110 | 0.82% | 5,576,857 | 2,780 | |
| J3245 | Injection, tildrakizumab, 1 mg | 265 | $136,974,230 | 0.82% | 1,278,409 | 4,100 | |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | 568 | $123,286,145 | 0.74% | 1,429,067 | 1,700 | |
| J1306 | Injection, inclisiran, 1 mg | 735 | $117,884,330 | 0.71% | 12,438,597 | 9,372 | |
| J2357 | Injection, omalizumab, 5 mg | 617 | $113,422,267 | 0.68% | 3,851,801 | 4,785 | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 593 | $101,026,285 | 0.61% | 2,848,101 | 3,245 | |
| Q4299 | Amnicore pro+, per square centimeter | 27 | $92,247,911 | 0.55% | 48,872 | 771 | |
| Q4239 | Amnio-maxx or amnio-maxx lite, per square centimeter | 38 | $89,761,821 | 0.54% | 47,039 | 835 | |
| J2778 | Injection, ranibizumab, 0.1 mg | 753 | $86,529,657 | 0.52% | 689,609 | 450 | |
| J9312 | Injection, rituximab, 10 mg | 336 | $76,913,551 | 0.46% | 1,277,588 | 3,200 | |
| J2350 | Injection, ocrelizumab, 1 mg | 96 | $74,686,070 | 0.45% | 1,718,391 | 13,500 | |
| Q4238 | Derm-maxx, per square centimeter | 34 | $72,887,582 | 0.44% | 81,745 | 1,853 | |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 447 | $70,990,965 | 0.43% | 1,950,771 | 2,940 | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 206 | $69,731,744 | 0.42% | 1,819,367 | 4,318 | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 3,290 | $68,531,588 | 0.41% | 495,106 | 120 | |
| Q4295 | Amnio tri-core amniotic, per square centimeter | 30 | $62,702,877 | 0.38% | 39,923 | 810 | |
| J1437 | Injection, ferric derisomaltose, 10 mg | 969 | $59,095,356 | 0.36% | 3,751,157 | 2,700 | |
| Q4221 | Amniowrap2, per square centimeter | 19 | $56,747,569 | 0.34% | 40,666 | 1,566 | |
| Q4290 | Membrane wrap-hydro, per square centimeter | 27 | $51,464,834 | 0.31% | 33,873 | 456 | |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 206 | $49,939,375 | 0.30% | 3,539,998 | 13,860 | |
| Q4282 | Cygnus dual, per square centimeter | 58 | $48,397,896 | 0.29% | 78,519 | 683 | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 1,179 | $46,586,077 | 0.28% | 20,179,038 | 11,915 | |
| Q4294 | Amnio quad-core, per square centimeter | 21 | $42,571,548 | 0.26% | 24,158 | 900 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Descriptions of HCPCS Level II codes are the official CMS descriptors, shown verbatim; CPT codes show a ClaimLight category in place of the descriptor. Data year 2024.
Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed